Taisho Pharmaceutical
As of the edition of 20 October 2026, Taisho Pharmaceutical runs 13 drugs, 9 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 1 |
| Went quiet | 3 |
| Total | 13 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Amoxicillin | none listed | 0 |
| Metronidazole | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Taurine | none listed | 0 |
| Orn-0829 hydrate | none listed | 0 |
| Ozoralizumab | none listed | 0 |
| Esflurbiprofen | none listed | 0 |
| Luseogliflozin | none listed | 0 |
| Falecalcitriol | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Mental health: 3 trials led
- Bones, joints and muscles: 2 trials led
- Nervous system: 2 trials led